It is highly expected that the development of new types of high-performance multifunctional AID inhibitors shown in this study would provide efficient US-triggered cancer therapy through inhibiting AID and could be widely used in treating AID-associated neoplasms and tumors with the advantages of cost-effectiveness, convenience, and noninvasiveness. The gene discussed is AICDA; the disease is cancer.